

## Variability of Treatment

---

Reference Number: F4580  
Date of Response: 27<sup>th</sup> June 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### **Request and Royal Devon and Exeter NHS Foundation Trust Response**

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments?

- Revolade (eltrombopag): **10**
- Nplate (romiplostim): **29**
- Doptelet (avatrombopag): **0**
- Tavlesse (fostamatinib): **0**

Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

**The Trust has treated 51 patients in the last six months for immune thrombocytopenia.**

Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

mycophenolate mofetil: **0**

surgery (splenectomy): **0**

**In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatment:**

- **rituximab**

**We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.**

**This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts,**

**CCG's providers and Trusts may allow identification of patients and should not be published.**

Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

**The Trust is not currently participating in any research trials for Immune Thrombocytopenia.**